Wyeth wins world award for investment in Scotland
Translational Medicine Research Collaboration Scoops "Best Investment in Europe" Award at La Baule
The award was made at the event in France in recognition of Wyeth's large financial investment, its determination to make the project succeed and for the number of highly skilled jobs created, projected at upwards of 120 jobs over five years in Scotland.
Wyeth Pharmaceuticals plans to invest an estimated £33m in the collaboration in its first five years with an option to extend for a further five years. Scottish Enterprise will invest up to £17.5m.
The £50 million collaboration comprises four of Scotland's leading universities (Aberdeen, Dundee, Edinburgh and Glasgow), Wyeth Pharmaceuticals, Scottish Enterprise and NHS Scotland Grampian, Greater Glasgow, Lothian and Tayside, and will provide new impetus for Scotland to lead the world in the development of personalised medicine, bringing new treatments to patients suffering from a range of serious illnesses.
TMRC has already invested almost £8 million of funding to support 28 new research projects covering a wide range of therapeutic areas including cardiovascular and metabolic disease, the central nervous system, oncology, inflammation, and women's health.
Topics
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.